Author Archives:

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Posted on by

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock




Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Enanta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $65.0 million. In addition, Enanta has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the public offering price, less underwriting discounts and commissions.


J.P. Morgan, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the SEC) on November 22, 2023 and became effective on February 8, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations.

Forward Looking Statements

Statements contained in this press release regarding Enanta’s expectations regarding the gross proceeds from the offering and the closing of the offering are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated closing date of the offering. These forward-looking statements are based upon Enanta’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, Enanta’s expectations regarding the completion of the offering, as well as those risks more fully discussed in the section entitled “Risk Factors” in Enanta’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and in Enanta’s subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts

Media and Investors Contact:
Jennifer Viera

jviera@enanta.com

Patient-Led NM Launches Statewide Summits and Video Campaign to Spotlight New Mexico’s Healthcare Crisis

Posted on by

Patient-Led NM Launches Statewide Summits and Video Campaign to Spotlight New Mexico’s Healthcare Crisis




Patient-Led NM Launches Statewide Summits and Video Campaign to Spotlight New Mexico’s Healthcare Crisis

A Call for New Mexicans to Demand Policy Reform That Secures Timely Access to High-Quality Care

Santa Fe, NM, Sept. 30, 2025 (GLOBE NEWSWIRE) — Patient-Led NM today announced the launch of a series of Healthcare Summits across New Mexico alongside a new patient video campaign designed to elevate the voices of those directly affected by the state’s ongoing healthcare challenges. The initiative aims to bring patients, clinicians, and policymakers together to address the pressing issues driving physician shortages, limited access to care, and escalating malpractice pressures.

New Mexico faces one of the most unstable healthcare environments in the nation. Data from the Medical Professional Liability Association shows that physicians in the state pay some of the highest malpractice premiums in the region, with rates 33% higher for internists and 50% higher for surgeons and OB/GYNs compared to neighboring states. Nearly 300 active-practice doctors have left New Mexico since 2019, further straining patient access in a state already struggling with provider shortages.

Patients Leading the Call for Reform

Patient-Led NM was created to ensure that patients themselves are at the center of the conversation on healthcare reform. The organization’s upcoming summits will provide a forum for residents to share their personal stories, highlight the human cost of delayed or unavailable care, and press for solutions that stabilize the medical system.

“Our daughter has to see nine specialists, all of whom are more than three hours away,” said Lindsey Saiz of Las Cruces, NM, a parent featured in the new video campaign. “That reality is stressful and unsustainable; I even had to quit my job because of all the travel to doctors appointments. Families like ours want lawmakers to understand the impact of their policies and that they are driving physicians out of New Mexico.”

Statewide Healthcare Summits

To confront these systemic barriers, Patient-Led NM’s Healthcare Summits will bring together patients, healthcare leaders, and policymakers to focus on practical, evidence-driven reforms. Each summit will spotlight lived experiences while opening dialogue on how malpractice reform, reimbursement adjustments, and GRT relief can collectively improve access to care.

John Wheeler, CEO of the Sacramento Mountains Foundation, noted the grassroots nature of the effort: “This movement is led by patients, and that’s what makes it so powerful. When individuals share their stories, it becomes impossible to ignore the real impact of the state-level policy decisions.”

Healthcare Summits Dates and Locations

Date Time Location Address
Oct. 21, 2025 5:00 – 7:00 PM NMSU Grants Branch Auditorium 1500 N. 3rd St.,
Grants, NM 87020
Nov. 3, 2025 5:00 – 8:00 PM UNM Continuing Education Conference Center 1634 University Blvd NE, Albuquerque, NM 87102
Nov. 13, 2025 5:00 – 7:00 PM Bataan Hall UNM Taos 121 Civic Plaza Drive,
Taos, NM 87571
Nov.19, 2025 5:00 – 8:00 PM Burrell College of Osteopathic Medicine Auditorium 3501 Arrowhead Dr, Las Cruces, NM 88001
Dec. 2, 2025 5:00 – 7:00 PM Virtual  

New Mexicans can register online at www.patientlednm.org.

Righting the Scales of Medical Malpractice

At the core of New Mexico’s healthcare crisis is a malpractice system widely regarded as one of the most volatile in the nation. While physicians everywhere must uphold the same rigorous national standards of care, those practicing in New Mexico face a legal environment that makes them significantly more vulnerable to lawsuits and unpredictable settlements.

“Healthcare delayed is justice denied,” said Annie Jung, Executive Director of the New Mexico Medical Society. “These summits will give patients a time and a place to share their stories and to work on shaping the policies that affect their daily lives.”

According to national industry data, New Mexico sees 50% more paid malpractice claims per capita than its neighboring states. Large claims, those that reach multimillion-dollar levels, are nearly triple what nearby states experience. As a result, liability premiums have surged well beyond the regional average, with providers here paying increases of almost 14% annually, nearly three times the national rate.

Dr. Angelina Villas-Adams, President of the New Mexico Medical Society, added: “Physicians want to care for New Mexicans, but the system has become unsustainable. Listening to patients is the first step toward meaningful reform.”

Experts attribute this instability to laws that tilt the system toward excessive litigation. These provisions have turned malpractice claims into a costly gamble that forces many doctors to reconsider practicing in New Mexico. Unlike other states, New Mexico’s laws remain unusually broad, leaving physicians exposed and patients with fewer choices.

Patient-Led NM argues that malpractice reform is the linchpin to stabilizing the system. Without addressing liability volatility, the organization warns, efforts to improve reimbursement rates or reduce tax burdens will fall short of ensuring consistent access to care.

Below-Cost Reimbursements and a Hidden Tax

Below-cost reimbursement rates and a hidden tax compound the state’s liability environment. New Mexico is one of only two states that taxes medical services through a gross receipts tax (GRT). While large hospital systems may receive partial deductions, independent physicians and small clinics often shoulder this tax directly out of already slim margins. The result is reduced capacity to expand services, modernize equipment, or even keep practices open, again pushing patients farther from care.

Troy Clark, CEO of the New Mexico Hospital Association, emphasized the broader impact: “Hospitals across the state are grappling with reimbursement challenges and workforce shortages. By coming together, patients and clinicians can ensure these realities are understood at every level of government.”

Patient-Led NM encourages all New Mexicans to participate by registering for a summit, viewing the new patient video campaign, and sharing their personal healthcare experiences.

For more information and to get involved, visit www.patientlednm.org.

Media Contact

Company Name: Patient-Led NM
Email: media@jjsassociates.us
Country: United States
Website: www.patientlednm.org

CONTACT: Media Contact
Company Name: Patient-Led NM
Email: media@jjsassociates.us
Country: United States
Website: www.patientlednm.org

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Posted on by

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases




Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a portion of investment to global development.

BURLINGAME, Calif. and TOKYO, Sept. 30, 2025 (GLOBE NEWSWIRE) — Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative medicines, announced it has entered into a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd (“Kyorin”) for development of Hinge Bio’s multispecific antibody-based therapeutic HB2198 in Japan for multiple autoimmune indications, starting with Systemic Lupus Erythematosus (“SLE”).

Per the terms of the agreement, Hinge Bio is to receive a $10 million upfront payment, is eligible to receive up to $95 million in milestone payments for the SLE indication, additional payments for other indications, and will lead global HB2198 development activities.  Kyorin will fund development, regulatory, marketing and commercialization activities in Japan and contribute a portion of investment to global development. The companies have established a Joint Steering Committee (JSC) to accelerate and potentially widen the development of HB2198 to treat multiple B cell mediated autoimmune disorders. 

“Hinge Bio is committed to developing life-changing medicines for patients with intractable diseases, driven by our proprietary GEM-DIMER platform,” said Chief Executive Officer Barry Selick, Ph.D. “We are thrilled to establish this validating collaboration with Kyorin to accelerate and broaden development of HB2198 in Japan for multiple autoimmune indications, beginning with SLE.”

“Our company is focused on autoimmune disorders as one of our key strategic therapeutic areas for research and development. We anticipate that this innovative treatment candidate, developed through our collaboration with Hinge Bio, will offer a new therapeutic option for patients suffering from autoimmune disorders,” said Yutaka Ogihara, President and CEO of KYORIN Pharmaceutical Co., Ltd.

Hinge Bio’s lead candidate from its GEM-DIMER™ platform, HB2198, is expected to enter clinical development during 2H 2025. The program seeks to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20 with enhanced natural killer cell engagement. Pre-clinical in vivo studies have demonstrated deeper and more rapid B cell depletion than has been reported for other antibody-based therapies. The therapeutic goal of HB2198 is to achieve a reset of the immune system through rapid and deep B cell depletion in both circulating blood and lymphoid tissues, with the convenience, accessibility, cost and safety benefits of an off-the-shelf antibody-based therapeutic.

About HB2198

Hinge Bio’s lead program HB2198, from its proprietary GEM-DIMER™ platform, is designed to improve efficacy, safety, and convenience for the treatment of B cell-mediated autoimmune disorders, such as SLE. HB2198 has demonstrated in vivo proof of concept to rapidly and deeply (>99%) deplete of B cells.  The therapeutic goal of HB2198 is to achieve a “reset” of the immune system through rapid and deep B cell depletion in both circulating blood and lymphoid tissues, without the challenges and toxicities associated with current treatments.  Hinge Bio anticipates opening a clinical trial in 2H 2025 to first treat SLE.

About Hinge Bio

Hinge Bio, Inc. is a privately held development-stage biotechnology company leveraging its proprietary GEM-DIMER™ platform to design and develop the next generation of therapeutics leading to address the problems of inadequate efficacy, resistance, and side effects in the fields of autoimmunity, inflammatory disease, cancer, and other disease. The GEM-DIMER™ technology platform enables the creation of multivalent, multispecific antibody-based therapeutics that are designed to bind their targets cooperatively allowing for dramatically enhanced biological activity and unique functionality. Hinge Bio is advancing a pipeline of programs with an initial focus on autoimmune disease.

About Kyorin

KYORIN operates under the corporate philosophy, “KYORIN continues to fulfil its mission of cherishing life and benefiting society by contributing to better health.” Based on this principle, we aim to continuously provide high-value new drugs that meet medical needs, striving to become a company that contributes broadly to people’s health. In drug discovery, we focus our research efforts on the therapeutic areas of pain and autoimmune disorders etc., working to create innovative new drugs that meet significant medical needs.

For more information, please visit https://www.kyorin-pharm.co.jp/en/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, include statements regarding the potential therapeutic benefits and applications of our product candidates; our ability to successfully advance our product candidates, undertake certain development activities (such as the initiation of clinical trials, clinical trial enrollment, the conduct of clinical trials and the announcement of top-line results) and accomplish certain development goals, and the timing of such events; the potential benefits of our collaboration with Kyorin; and the scope and strength of our intellectual property portfolio. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the fact that our collaboration with Kyorin is subject to early termination in certain circumstances, the possibility of unexpected expenses or other demands on our cash resources, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Meru Advisors on Behalf of Hinge Bio:

Patrick Till

ptill@meruadvisors.com or info@hingebio.com 

Learn more at www.hingebio.com

NMDP Surpasses $100 Million Comprehensive Campaign Goal to Expand Patient Access, Remove Financial Barriers to Life-saving Transplants

Posted on by

NMDP Surpasses $100 Million Comprehensive Campaign Goal to Expand Patient Access, Remove Financial Barriers to Life-saving Transplants




NMDP Surpasses $100 Million Comprehensive Campaign Goal to Expand Patient Access, Remove Financial Barriers to Life-saving Transplants

The announcement, made at the 18th annual NMDP Gala in Minneapolis, represents significant philanthropic support of the organization’s mission to save lives through cell therapy

MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) — NMDP℠ (formerly Be The Match®), a global nonprofit leader in cell therapy, announced that is has exceeded its $100 million comprehensive campaign goal, raising more than $102 million through the generosity of thousands of supporters and partners. This milestone reflects the power of philanthropy to remove financial barriers for patients, accelerate groundbreaking research, and expand access so that more patients can receive their life-saving cell therapy. Through this effort, NMDP has impacted more than 50,469 lives over the last six years.

Financial barriers remain the number one challenge reported by patients seeking transplants. Each day, NMDP receives an average of 15 grant requests from patients needing help with transplant-related expenses like housing, transportation, and prescription medications. Since 2019, NMDP has delivered more than $39.1 million in patient financial assistance. In 2024 alone, the organization provided $6.6 million in aid to more than 3,000 patients.

A Media Snippet accompanying this announcement is available by clicking on this link.

In addition to easing the financial burden on patients, campaign support has fueled innovation across NMDP’s mission. More than $20 million has been invested in research, including advancing clinical trials through NMDP’s Donor for All initiative, which seeks to expand the availability of donors for every patient in need of a transplant. Another $11.1 million has gone into NMDP’s donor and registry support, ensuring the organization remains a world-class partner for patients, donors, and the global transplant community. Together, these efforts represent a comprehensive approach: meeting patients’ urgent financial needs today while also building the scientific and systemic foundation of the future. In addition to these priority areas, the balance of funds raised supported the mission broadly, ensuring flexibility to meet emerging needs.

“When we launched this comprehensive campaign, our goal was to impact 10,000 lives every year by 2028. This milestone reminds us that we are well on our way as this year we have surpassed 8,000 lives saved for the first time in our organization’s history,” said Amy Ronneberg, CEO of NMDP. “Together with our donors and partners, we’re easing financial burdens for families, fueling groundbreaking research, and strengthening the donor registry, but our work isn’t done. At NMDP, we are committed to building on this momentum to help even more patients, donors, and families.”

The real-life impact of this milestone was front and center on Friday, September 26, at the annual NMDP Gala in Minneapolis, sponsored by Hollstadt Consulting. The Gala brought together more than 400 patients, families, donors, physicians, and supporters to celebrate the generosity that makes milestones like this possible. Attendees raised $1.2 million at the Gala and witnessed unforgettable moments, such as the first-time meeting between Betsy Gabler and her donor, Erica Buck. Gabler, a Minnesota resident, was diagnosed with acute myeloid leukemia and found a donor on the NMDP Registry. She underwent a blood stem cell transplant in 2022. Now 63 years old, Gabler had the opportunity to meet Buck, a mom from Montana, whose blood stem cells saved her life.

“Stories like that of Betsy and Erica highlight why this work is so important,” said Erica Jensen, Senior Vice President, Strategy and Advancement, NMDP. “This $100 million milestone belongs to every donor, partner, and community member who joined us in this campaign. It is a reminder that NMDP is driving progress that helps patients live longer, healthier lives. This is not the finish line — it’s the foundation for innovative fundraising strategies that ensure the impact we’ve created won’t stop with this campaign but will continue to grow for years to come.”

The campaign kicked off in 2019 following a feasibility study and was designed to deepen a culture of philanthropy at NMDP and directly support the organization’s goal of impacting 10,000 lives annually. The comprehensive campaign unites multiple streams of giving, including annual contributions, planned gifts, and program support, into one coordinated effort that advances NMDP’s mission of saving lives through cell therapy. To learn more, visit giving.nmdp.org.

About NMDP

At NMDP, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives.

CONTACT: Media Contact:
Erica Sevilla
Public Relations Manager, NMDP
esevilla@nmdp.org

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

Posted on by

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results




YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its unaudited financial results for the six months ended June 30, 2025.

Management Commentary

“With the closing of our business combination with Breeze Holdings Acquisition Corp. (“Breeze Holdings’) in August and the concurrent closing of a private investment in public equity financing, securing $13.2 million in gross proceeds to support our wholly-owned subsidiary YD Biopharma Limited (“YD Biopharma”)’s liquidity and capital resources, we are now a publicly traded biotech platform with the capital and structure needed to accelerate innovation,” said Dr. Ethan Shen, Chairman of the Board and CEO of YD Bio Ltd.

“Despite a slight decrease in net revenue, we managed to continue investing in general and administrative functions and R&D to expand capacity. We also advanced two licensed patents to execute growth strategy during the reporting period.”

“Our vision remains to deliver minimally invasive, early cancer detection globally and pioneer regenerative ophthalmology therapies. As previously announced, through exclusive licensing with EG BioMed Co., Ltd. (“EG BioMed”), we’ve launched a DNA methylation-based pancreatic cancer screening LDT and will introduce a breast cancer recurrence monitoring LDT later this year. In partnership with 3D Global Biotech Inc. (“3D Global”), we are preparing corneal stem-cell and exosome-based treatments for dry eye, glaucoma and corneal injury, with clinical trials slated for 2027. Simultaneously, our proven track record as a supplier of investigational drugs and ancillary materials underpins a robust clinical-trial services business.”

“We believe YD Bio Limited is positioned to capture a share of the multibillion-dollar oncology diagnostics, ocular therapeutics and clinical-trial services markets. Our strengthened balance sheet, public-market profile and diversified pipeline set the stage for sustainable revenue growth, margin expansion and long-term value creation for patients, partners and shareholders,” Dr. Shen said.

YD Biopharma’s Half Year 2025 Financial Results

YD Biopharma’s vision is to deliver early cancer detection globally, offering patients additional less invasive treatment options. It will focus on product development, equipment upgrades, and capacity expansion to meet customer quality and volume standards. YD Biopharma plans to achieve this through new products, acquisitions, licensing, proprietary medical-industry IP, and investments in global manufacturing processes. YD Biopharma will also grow its IP portfolio’s value to support worldwide product licensure.

Net Revenue

Net revenue fell by $20,973, or 9%, to $204,007 for the six months ended June 30, 2025, from $224,980 in the prior year. The top five products accounted for 56% of total revenue during the first half year of 2025, and the decline in net revenue was due to a change in product mix. 

Top five individual products by revenue for the six months ended June 30, 2025:

Keytruda injection (Drugs)   $ 42,503  
Exolens Hioxifilcon (Contact lenses)     35,000  
Pharmorubicin Injection (Drugs)     17,938  
12-Lead Electrocardiograph (Medical and related products)     10,048  
Solu-Medrol Injection (Drugs)     8,478  
Subtotal   $ 113,967  

Top five individual products by revenue for the six months ended June 30, 2024:

PVA Eye Cleansing Wipes (Medical and related products)   $ 49,077  
Keytruda injection (Drugs)     24,837  
Fluorescence Cell Counter and Viability Analyzer (Medical and related products)     23,326  
Giotrif Film-Coated Tablets (Medical and related products)     14,915  
Faslodex Solution for injection (Drugs)     14,175  
Subtotal   $ 128,330  

Cost of Revenue

Cost of revenue declined by $20,668, or 13%, to $135,212 for the six months ended June 30, 2025, from $155,880 a year earlier, reflecting primarily the 9% drop in net revenue. Cost of revenue consists mainly of purchase costs of products for resale.

Gross Profit

Gross profit was unchanged at $69,000 for the six months ended June 30, 2025 and 2024. We believe that, as we will grow net revenue through new markets and expanded distribution, our gross profit will also increase. We plan to accomplish this through the following:

●     improving resale product and raw material sources;

●     increasing and diversifying our customer base;

●     introducing new product lines and subcontractors with higher margins;

●     commencing new cancer early detection services;

●     establishing additional licensing agreements;

●     reducing component costs through greater purchasing power and scalability; and

●     expanding strategic relationships with component providers.

Operating Expenses

Operating expenses totaled $2.0 million for the six months ended June 30, 2025, up $1.8 million from $262,264 in the prior period, driven by $1.0 million in general and administrative fees for expansion and restructuring and $0.8 million in research and development expenses for two licensed patents and know-how.

Net Loss

YD Biopharma has operated primarily as a development stage company since its formation. Net loss was $1.9 million for the six months ended June 30, 2025, compared to $0.17 million in the prior period, driven by higher professional and consultancy fees incurred in connection with our business combination with Breeze   Holdings, R&D expenses, and staff costs linked to business expansion.

Cash and Cash Equivalents

Cash and cash equivalents including unrestricted cash with maturities of three months or less stood at $469,520 as of June 30, 2025, down from $3,132,298 at December 31, 2024, primarily due to general and administrative expenses and R&D spending.

Major Developments

YD Biopharma advanced ocular therapies via a 3D Global license for corneal mesenchymal stem cells and exosomes, supporting an IRB-approved corneal specimen study at Shuang-Ho Hospital. In 2025, It initiated clinical trial applications for exosome-based contact lenses and artificial tears for dry eye.

YD Biopharma is also expanding into oncology diagnostics through EG BioMed. In June 2024, it secured patents, technology, and U.S. market authorization for high-accuracy pancreatic cancer methylation detection, with plans for a U.S. independent lab and healthcare partnerships. On September 30, 2024, it signed an exclusive license for breast cancer detection across the U.S., Europe, and Asia, with a 20% revenue royalty to EG BioMed, for 20 years with automatic 5-year renewal.

About YD Bio Limited

YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio’s current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

Posted on by

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes




Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes:


  • $500 million aggregate principal amount of its 4.200% senior notes due 2031 (the “2031 notes”) at the issue price of 99.874% of their principal amount;
  • $750 million aggregate principal amount of its 4.473% senior notes due 2032 (the “2032 notes”) at the issue price of 100.000% of their principal amount;
  • $750 million aggregate principal amount of its 4.794% senior notes due 2035 (the “2035 notes”) at the issue price of 100.000% of their principal amount; and
  • $500 million aggregate principal amount of its 4.894% senior notes due 2037 (the “2037 notes” and, together with the 2031 notes, the 2032 notes and the 2035 notes, the “notes”) at the issue price of 100.000% of their principal amount.

The Offering is expected to close on or about October 7, 2025, subject to the satisfaction of customary closing conditions. The notes will pay interest on a semi-annual basis.

Thermo Fisher intends to use the net proceeds from the sale of the notes for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose.

The joint book-running managers for the Offering are J.P. Morgan Securities LLC, ING Financial Markets LLC, Mizuho Securities USA LLC and Scotia Capital (USA) Inc.

The Offering is being made pursuant to an effective registration statement on Form S-3ASR (File No. 333-285159) filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the “SEC”) on February 24, 2025 and only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and an issuer free writing prospectus have been filed, and a prospectus supplement relating to the Offering will be filed, with the SEC, to which this communication relates. Prospective investors should read the issuer free writing prospectus, preliminary prospectus supplement and accompanying prospectus forming a part of that registration statement and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Offering will arrange to send you the prospectus and the prospectus supplement if you request it by calling J.P. Morgan Securities LLC collect at 1-212-834-4533, ING Financial Markets LLC toll-free at 1-877-446-4930, Mizuho Securities USA LLC toll-free at 1-866-271-7403, or Scotia Capital (USA) Inc. toll-free at 1-800-372-3930.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about timing and completion of the Offering and Thermo Fisher’s intended use of proceeds therefrom. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the Offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” section of the prospectus dated February 24, 2025 and the preliminary prospectus supplement dated September 30, 2025 related to the Offering and in Part 1, Item 1A. “Risk Factors” of Thermo Fisher’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the other documents incorporated by reference into the prospectus and prospectus supplement, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Contacts

Media Contact Information:

Sandy Pound

Thermo Fisher Scientific

Phone: 781-622-1223

E-mail: sandy.pound@thermofisher.com

Investor Contact Information:

Rafael Tejada

Thermo Fisher Scientific

Phone: 781-622-1356

E-mail: rafael.tejada@thermofisher.com

Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors

Posted on by

Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors




Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors

SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a clinical-stage biotechnology company developing a first-in-class, oral small molecule HPV E5 protein inhibitor targeting cancers caused by the human papillomavirus (“HPV”), today announced the successful completion of a $12 million convertible note financing.

The financing was led by Steven Lebow, who will join Toragen’s Board of Directors along with his designee, Dr. Scott Rasgon. GenHenn Capital also participated with a significant investment and will be represented on the Board by Bill Hagaman, COO of GenHenn Capital. In addition, Cathleen May, PhD, will assume the Board seat of the late Paul Engler, representing the Paul F. and Virginia J. Engler Foundation.

“This financing enables us to advance the next critical steps in developing TGN-S15, our lead candidate, and prepare for our upcoming clinical trial,” said Sandra Coufal, MD, CEO of Toragen. “We are grateful for the support of our investors and are excited to welcome four distinguished new members to our Board who bring deep expertise and commitment to our mission of developing an effective treatment for HPV-driven cancers.”

The majority of proceeds from this financing will support CMC and IND-enabling studies for TGN-S15.

About Steven E. Lebow

Steven Lebow is widely recognized in the investment banking community for his 21-year tenure as Managing Director at Donaldson, Lufkin & Jenrette (DLJ), where he led the Retail Investment Banking Group and advised clients across the U.S., Europe, and Latin America.

He has been an early investor in companies including Costco, Starbucks, PetSmart, Dick’s Sporting Goods, and Ulta Beauty, generating returns between 100x and 600x and helping drive their combined market capitalization above $600 billion. In recognition of his achievements, Steven was inducted into the DLJ “Hall of Fame” in 1995.

He later co-founded Global Retail Partners, a venture capital firm that became GRP Partners, and has continued to be a prominent figure in finance and investment. Steven earned his BA in Economics and Political Science, magna cum laude and Phi Beta Kappa, from UCLA and an MBA from the Wharton School at the University of Pennsylvania, where he was awarded the Exxon Fellowship.

About Toragen

Toragen is focused on targeting the root cause of HPV-induced cancers. The company has successfully completed a Phase 1 clinical trial in Stage 4 HPV+ head and neck cancer patients, meeting both primary endpoints of safety and maximum tolerated dose. The trial also demonstrated drug activity in 53% of patients treated. Learn more at www.toragen.com.

Contacts

Toragen, Inc.

Sandra Coufal, MD

Chief Executive Officer

scoufal@toragen.com

Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research

Posted on by

Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research




Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research

Award Highlights Critical Role of Philanthropy Amid Federal Cancer Research Shortfalls

BOSTON–(BUSINESS WIRE)–The global cancer research community today celebrated a historic milestone, awarding the inaugural Stephenson Global Prize to Dr. Frank McCormick for his groundbreaking discoveries that have transformed the fight against pancreatic cancer.


Pancreatic cancer is the third leading cause of cancer-related death in the U.S. and carries the lowest five-year survival rate, just 13%. Despite its devastating toll, federal funding for pancreatic cancer research has long lagged behind other major cancers. Recent shortfalls and uncertainty in NIH funding have only heightened the urgent need for private philanthropy to fill this gap. The Stephenson Global Prize—presented with a $1 million unrestricted award—is designed to empower visionary researchers with the resources to accelerate discoveries that could change the trajectory of this deadly disease.

In honor of their beloved wife and mother, Toni Stephenson, A. Emmet Stephenson Jr. and Tessa Stephenson Brand made a $150 million philanthropic gift that established the Stephenson Global Prize and catalyzed the launch of the Stephenson Global Pancreatic Cancer Research Institute (SGPCRI).

“We created the Stephenson Global Prize because too many brilliant ideas in pancreatic cancer research never get the funding they need,” said A. Emmet Stephenson. “With federal resources stretched thin, philanthropy must step in to ensure that scientists like Dr. McCormick have the freedom to pursue breakthroughs without barriers.”

Tessa Stephenson Brand added, “Every day, families are touched by this devastating disease. By fueling innovative research, we can accelerate the breakthroughs that will save lives.”

Dr. McCormick, Professor at the UCSF Helen Diller Family Comprehensive Cancer Center, was honored for uncovering how mutations in the KRAS gene—present in more than 90% of pancreatic ductal adenocarcinomas—drive tumor growth. Once thought impossible to target, this discovery has paved the way for new therapies and brought renewed hope to patients and families worldwide.

“This recognition is deeply meaningful,” said Dr. McCormick. “Pancreatic cancer remains one of the most challenging diseases we face, and I’m honored to share this award with my lab as we continue exploring new ways to target KRAS and develop therapies that could change lives.”

The award was presented during the AACR Special Conference on Advances in Pancreatic Cancer Research in Boston, before an international audience of scientists, clinicians, and advocates united in the fight against one of the world’s deadliest cancers.

“By investing in early detection, prevention, treatment, translational research, and scientific discovery, the annual Stephenson Global Prize and Scholar Grants not only celebrate transformative achievements but also fuels hope and inspires perseverance, reminding researchers that breakthroughs are within reach,” said Jennifer Chun Kim, Executive Director of SGPCRI.

Beyond the Prize: A Comprehensive Strategy

In addition to the Stephenson Global Prize, SGPCRI is advancing a multi-pronged approach to accelerate progress against pancreatic cancer:

  • Stephenson Global Scholar Grants: Empowering investigators to pursue innovative ideas, these grants provide substantial funding to fuel transformative research. By cutting through bureaucracy and eliminating red tape, SGPCRI fosters true innovation and courageous risk-taking, accelerating discoveries with the potential to revolutionize treatment and detection while improving survival rates and patient outcomes. This year’s $5.3 million inaugural scholar grant recipients include:

    • Dr. Matthew Vander Heiden (MIT): Developing a multimodal platform that combines stool, blood, and CT imaging to detect pancreatic cancer before symptoms appear, leveraging changes in organ function as early warning signs.
    • Dr. Forest White and Dr. Tyler Jacks (MIT): Using mass spectrometry to identify new peptide antigens that emerge after KRAS inhibition, enabling vaccine and BiTE strategies that link targeted therapy with immunotherapy.
  • Annual Stephenson Pancreatic Cancer Symposium: Each year, SGPCRI hosts this premier gathering to honor Global Prize recipients, showcase breakthroughs achieved through the Scholar Grants, and unite the research community. The symposium serves as a vital platform for collaboration and momentum in the global fight against pancreatic cancer.

About the Stephenson Global Pancreatic Cancer Research Institute (SGPCRI)

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is dedicated to transforming the future of pancreatic cancer research through groundbreaking innovation, global collaboration, and strategic funding initiatives. Established through a transformative $150 million gift from philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand, SGPCRI is committed to advancing early detection, pioneering treatments, and high-impact research to improve patient outcomes. Working with leading scientists, clinicians, and institutions worldwide, SGPCRI fosters collaboration to accelerate breakthroughs in the fight against one of the world’s most challenging cancers. For more information, visit us on our website or follow us on LinkedIn and X.

Contacts

Media Contact:
Kria Sakakeeny, (401) 359-2219, kria@ekkopr.com

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

Posted on by

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer




The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1

Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth

LONG BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) — The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of Pedro Malha as President and Chief Executive Officer, effective October 1, 2025. He succeeds Marla Beck, who is stepping down as President and CEO effective September 30, 2025, and will remain in an advisory role.

Brent Saunders, Chairman of the Board, stated, “Pedro is an accomplished leader with broad industry experience at leading multinational companies in the healthcare and medical device sectors. His ability to navigate complex global markets and build collaborative, high-performing teams makes him the right person to lead BeautyHealth into its next chapter. We are also grateful for Marla’s strong leadership during a pivotal period of transformation, which has left BeautyHealth well positioned for sustainable and profitable growth.”

During her tenure, Ms. Beck guided BeautyHealth through a period of significant change, reigniting the Company’s science-backed innovation pipeline, streamlining and upgrading manufacturing, quality control, and operations, and refining the cost structure to strengthen margins and return the Company to profitability. She also reinforced Hydrafacial’s dual commitment to both providers and consumers, ensuring it remains the gold standard in performance skin health.

Ms. Beck said: “I am incredibly proud of what we have accomplished together to strengthen BeautyHealth’s foundation and future. With the right team and strategy in place, I believe now is the right time to welcome a new CEO to lead the Company into its next phase of growth. BeautyHealth has a robust pipeline of innovation and bold brand initiatives currently underway, and I look forward to watching the Company continue to thrive under Pedro’s leadership.”

Mr. Malha joins BeautyHealth following a distinguished global career spanning more than two decades across the healthcare and medical device industries. He most recently served as Worldwide Division President and Corporate Officer of Abbott Laboratories, where he led the neuromodulation business. Prior to that, he held senior leadership roles overseeing multiple global business units at Zimmer Biomet Holdings, Abbott, and Johnson & Johnson in Europe, where he consistently delivered growth and operational excellence. He holds an MBA from Boston University and a Bachelor of Science from Bentley University.

“I am honored to join BeautyHealth and lead this exceptional Company into the future,” stated Mr. Malha. “Hydrafacial is a category-defining brand with unmatched potential at the intersection of beauty and health. I look forward to working alongside the Board, the leadership team, and our global community of providers to shape the future of skin health through continued science-backed innovation and operational excellence, while accelerating profitable growth and creating lasting value for stakeholders around the world.”

About The Beauty Health Company

The Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/ and learn more at beautyhealth.com or LinkedIn.

Contacts: 
Hydrafacial Media Contact: press@beautyhealth.com
Investors: IR@beautyhealth.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6d01c322-0bb8-4a02-bb64-eba8c518ee54

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Posted on by

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares




Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an underwritten public offering. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares (and common shares underlying pre-funded warrants) sold in the proposed public offering, on the same terms and conditions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering may be completed, or as to the actual size or terms of the proposed public offering. All securities to be sold in the proposed public offering will be offered by the Company.


The Company plans to allocate the net proceeds for the acceleration of commercial launch, with an emphasis on sales expansion, marketing investment, and enhancing payer coverage and reimbursement infrastructure. These investments are designed to maximize near-term adoption while laying the foundation for long-term revenue growth and a sustainable commercial presence in the Alzheimer’s treatment landscape.

Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for this proposed public offering.

The proposed public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-289792) filed with the Securities and Exchange Commission (“SEC”) on August 22, 2025, and declared effective by the SEC on August 29, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering, when available, may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.

This proposed public offering will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion, timing and size of the Company’s proposed public offering, the grant to the underwriter of an option to purchase additional securities, the satisfaction of customary closing conditions, and the intended use of proceeds therefrom. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with the SEC, including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and our periodic reports on Form 10-Q and Form 8-K filed with the SEC available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Contacts

For further information:

Investor Relations

IR@alphacognition.com
https://www.alphacognition.com/